Camlin Fine

Which are the latest news on Camlin Fine?

Why is Camlin Fine Sciences Ltd falling/rising?

As of 03-Aug, Camlin Fine Sciences Ltd's stock price is at 128.25, reflecting a slight rise but underperforming the sector. Despite recent gains, the stock has significant long-term declines and weak fundamentals, indicating potential challenges ahead.

As of 03-Aug, Camlin Fine Sciences Ltd is experiencing a slight rise in its stock price, currently at 128.25, with a change of 0.55 (0.43%) upward. This increase follows a two-day consecutive gain where the stock has risen by 1.83%. However, despite this recent uptick, the stock has underperformed compared to the sector by -0.98% today.<BR><BR>In the broader context, the stock has shown significant declines over longer periods, with a year-to-date drop of -13.55% and a staggering -52.76% over the past year. The company's fundamentals are weak, evidenced by a -30.80% compound annual growth rate in operating profits over the last five years and a high debt to EBITDA ratio of 7.60 times, indicating low ability to service debt. Additionally, the company has reported a -110.3% decline in profits over the past year, which raises concerns about its long-term viability.<BR><BR>Investor participation is also declining, as indicated by a -37.98% drop in delivery volume compared to the five-day average. Furthermore, institutional investors have reduced their stakes by -2.32% in the previous quarter, reflecting a lack of confidence in the company's prospects. <BR><BR>While the stock is currently trading at a discount compared to its peers and has attractive valuation metrics, the overall negative performance in both short and long-term returns, coupled with weak fundamentals, suggests that the stock's rise may be temporary amidst a backdrop of significant challenges.

How big is Camlin Fine?

As of 10th June, Camlin Fine Sciences Ltd has a market capitalization of 2,536.00 Cr, with recent net sales of 1,748.70 Cr and a net profit of 27.63 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Camlin Fine Sciences Ltd has a market capitalization of 2,536.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,748.70 Cr, while the sum of Net Profit for the same period is 27.63 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 901.67 Cr, and Total Assets amount to 1,958.75 Cr.

Who are in the management team of Camlin Fine?

The management team of Camlin Fine includes Ashish S Dandekar (Chairman & Managing Director), Nirmal V Momaya (Managing Director), and several independent directors, along with other key members responsible for the company's operations and strategic direction.

The management team of Camlin Fine includes the following key members:<BR><BR>1. **Ashish S Dandekar** - Chairman & Managing Director<BR>2. **Nirmal V Momaya** - Managing Director<BR>3. **Anagha S Dandekar** - Director<BR>4. **Arujun S Dukane** - Executive Director (Technical)<BR>5. **Amol Shah** - Independent Director<BR>6. **Sutapa Banerjee** - Independent Director<BR>7. **Mahabaleshwar G Palekar** - Independent Director<BR>8. **Harsha Raghavan** - Director<BR>9. **Conrad D Souza** - Independent Director<BR>10. **Pradip M. Kanakia** - Independent Director<BR>11. **Rahul Sawale** - Vice President & Company Secretary<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Camlin Fine?

Camlin Fine's peers include Rossari Biotech, Jubilant Agri, NOCIL, Tatva Chintan, DDev Plastiks, Bhansali Engg., Titan Biotech, S H Kelkar & Co., and Vidhi Specialty. Camlin Fine has below-average management risk and growth, with a 1-year return of -57.53%, the lowest among its peers.

Peers: The peers of Camlin Fine are Rossari Biotech, Jubilant Agri, NOCIL, Tatva Chintan, DDev Plastiks, Bhansali Engg., Titan Biotech, S H Kelkar & Co., and Vidhi Specialty.<BR><BR>Quality Snapshot: Excellent management risk is observed at Rossari Biotech, while Average management risk is found at Jubilant Agri, NOCIL, Tatva Chintan, DDev Plastiks, Bhansali Engg., Titan Biotech, S H Kelkar & Co., and Vidhi Specialty, and the rest. Below Average management risk is noted for Camlin Fine and Indokem. Growth is Excellent at Jubilant Agri, Average at DDev Plastiks, and Below Average at NOCIL, Tatva Chintan, Bhansali Engg., Titan Biotech, S H Kelkar & Co., Vidhi Specialty, Camlin Fine, and Indokem. Capital Structure is Excellent at Rossari Biotech, Jubilant Agri, NOCIL, Tatva Chintan, DDev Plastiks, Bhansali Engg., Titan Biotech, and Vidhi Specialty, while Average is seen at S H Kelkar & Co., and Below Average at Camlin Fine and Indokem.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Titan Biotech at 412.73%, while Camlin Fine has the lowest at -57.53%. Camlin Fine's return is significantly lower than all its peers. Additionally, the peers with negative six-month returns include Rossari Biotech, DDev Plastiks, S H Kelkar & Co., and Vidhi Specialty.

What does Camlin Fine do?

Camlin Fine Sciences Ltd is a small-cap company in the specialty chemicals industry, reporting net sales of ₹425 Cr and a net profit of ₹88 Cr for March 2026. It was incorporated in 1993 and underwent a name change in 2006 after a demerger from Camlin Limited.

Overview:<BR>Camlin Fine Sciences Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated on November 30, 1993, as Camlicon Consultants Private Limited. It underwent a name change to Camlin Fine Chemicals Private Limited on June 1, 2006, following the demerger of the Fine Chemicals Division from Camlin Limited, effective July 1, 2006. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 425 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 88 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 2,536 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.54 <BR>Return on Equity: -0.69% <BR>Price to Book: 2.45<BR><BR>Contact Details:<BR>Address: Plot No F/11 & F/12 WICEL, Central Road Andheri(East) Mumbai Maharashtra : 400093 <BR>Tel: 91-22-67001000 <BR>Email: secretarial@camlinfs.com <BR>Website: http://www.camlinfs.com

Should I buy, sell or hold Camlin Fine Sciences Ltd?

Are Camlin Fine Sciences Ltd latest results good or bad?

Camlin Fine Sciences Ltd's latest results show a standalone net loss of ₹0.41 crores, down from a profit of ₹27.88 crores last year, indicating significant operational challenges. While consolidated net profit improved to ₹88.20 crores, the overall decline in sales and sharp contraction in operating margins suggest caution for investors.

Camlin Fine Sciences Ltd's latest results indicate a challenging situation for the company. In Q4 FY26, the company reported a standalone net loss of ₹0.41 crores, a significant decline from a profit of ₹27.88 crores in the same quarter the previous year. This reflects serious operational pressures.<BR><BR>Consolidated net profit showed an improvement to ₹88.20 crores, but this figure is misleading as it represents a dramatic increase from a loss of ₹0.72 crores year-on-year. The company's net sales also decreased by 1.57% year-on-year, highlighting stagnation in revenue generation.<BR><BR>One of the most concerning aspects is the sharp contraction in operating margins, which fell to 4.99% from 14.38% a year earlier. This decline is attributed to rising costs and pricing pressures, with interest expenses hitting an all-time high of ₹22.98 crores, further straining the company's financial health.<BR><BR>Overall, while there are some positive signs in the consolidated results, the standalone performance and the significant margin erosion suggest that the company is facing substantial challenges. Investors may want to approach with caution given the current operational difficulties and financial pressures.

When is the next results date for Camlin Fine Sciences Ltd?

Camlin Fine Sciences Ltd will announce its results on 26 May 2026.

Camlin Fine Sciences Ltd is scheduled to declare its results on 26 May 2026.

Is Camlin Fine technically bullish or bearish?

As of December 3, 2025, Camlin Fine's technical trend has shifted to a moderate bearish stance, driven by bearish momentum in the MACD, confirming moving averages, and Bollinger Bands, despite mixed signals from the KST.

As of 3 December 2025, the technical trend for Camlin Fine has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing bearish momentum, daily moving averages confirming a bearish trend, and Bollinger Bands indicating bearish conditions on both weekly and monthly time frames. The KST presents a mixed signal with a bearish weekly reading and a bullish monthly reading, but overall, the prevailing bearish indicators suggest a downward pressure on the stock.

Is Camlin Fine overvalued or undervalued?

As of November 25, 2025, Camlin Fine's valuation has shifted from attractive to fair, indicating it is overvalued with a PE ratio of 327.96 and an EV to EBITDA of 19.86, especially when compared to peers like Solar Industries and Godrej Industries.

As of 25 November 2025, the valuation grade for Camlin Fine has moved from attractive to fair. Based on the analysis, the company appears to be overvalued. Key ratios indicate this, with a PE ratio of 327.96, an EV to EBITDA of 19.86, and a ROE of only 0.98%. <BR><BR>In comparison to its peers, Camlin Fine's valuation metrics stand out unfavorably; for instance, Solar Industries has a PE of 90.94 and an EV to EBITDA of 55.97, while Godrej Industries, which is rated attractive, has a PE of 35.73 and an EV to EBITDA of 39.89. Additionally, despite a strong performance year-to-date with a return of 19.77% compared to the Sensex's 8.25%, the long-term outlook shows a decline over three years, further supporting the notion that Camlin Fine is currently overvalued.

How has been the historical performance of Camlin Fine?

Camlin Fine's historical performance has been mixed, with net sales increasing to 1,666.53 Cr in Mar'25 but a significant decline in profitability, resulting in a net loss of -139.05 Cr. While total assets grew, cash flow from operations decreased, indicating inconsistent financial health.

Answer:<BR>The historical performance of Camlin Fine shows a mixed trend over the years, with significant fluctuations in key financial metrics.<BR><BR>Breakdown:<BR>Camlin Fine's net sales increased from 1,412.09 Cr in Mar'22 to 1,666.53 Cr in Mar'25, although it peaked at 1,681.56 Cr in Mar'23. Total operating income followed a similar pattern, reaching 1,666.53 Cr in Mar'25. However, total expenditure also rose, reaching 1,458.41 Cr in Mar'25, up from 1,259.29 Cr in Mar'22. Operating profit (PBDIT) showed some improvement, increasing to 222.57 Cr in Mar'25 from 185.83 Cr in Mar'22, but profit before tax declined significantly to 49.03 Cr in Mar'25 from 94.11 Cr in Mar'22. The net profit turned negative in Mar'25 at -139.05 Cr, down from 60.68 Cr in Mar'22. The company's total assets increased to 1,958.75 Cr in Mar'25 from 1,763.70 Cr in Mar'22, while total liabilities also rose to 1,958.75 Cr in Mar'25 from 1,763.70 Cr in Mar'22. Cash flow from operating activities decreased to 26.00 Cr in Mar'25 from 145.00 Cr in Mar'22, and the closing cash and cash equivalents improved to 104.00 Cr in Mar'25 from 107.00 Cr in Mar'22. Overall, while revenues have shown growth, profitability has been inconsistent, leading to a negative net profit in the latest fiscal year.

Who are the top shareholders of the Camlin Fine?

The top shareholders of Camlin Fine include promoters with the largest individual holding by Ashish Subhash Dandekar at 10.52%, mutual funds at 3.38%, foreign institutional investors at 2.88%, and individual investors collectively owning 30.98%, with Nirmal Vinod Momaya as the highest public shareholder at 1.92%.

The top shareholders of Camlin Fine include the promoters, who hold the majority of the shares. Among them, Ashish Subhash Dandekar has the highest individual holding at 10.52%. Additionally, mutual funds collectively hold 3.38% of the shares through six schemes, while foreign institutional investors (FIIs) hold 2.88% through 48 different entities. The highest public shareholder is Nirmal Vinod Momaya, who holds 1.92%. Individual investors collectively own 30.98% of the company.

Has Camlin Fine declared dividend?

Yes, Camlin Fine Sciences Ltd has declared a dividend of 45% (0.45 per share) with an ex-date of July 28, 2016. However, the current dividend yield is 0%, despite significant price appreciation over the past five years.

Camlin Fine Sciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 28 Jul 16<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was 121.16%, with a dividend return of 0%, resulting in a total return of 121.16%.<BR><BR>In the 1 year period, the price return was 181.64%, with a dividend return of 0%, resulting in a total return of 181.64%.<BR><BR>In the 2 years period, the price return was 58.52%, with a dividend return of 0%, resulting in a total return of 58.52%.<BR><BR>In the 3 years period, the price return was 132.74%, with a dividend return of 0%, resulting in a total return of 132.74%.<BR><BR>In the 4 years period, the price return was 51.6%, with a dividend return of 0%, resulting in a total return of 51.6%.<BR><BR>In the 5 years period, the price return was 518.24%, with a dividend return of 0%, resulting in a total return of 518.24%.<BR><BR>Overall, while Camlin Fine has declared a dividend in the past, the current dividend yield is 0%. However, the total returns over various periods demonstrate significant price appreciation, particularly over the 5-year period.